NCI, LOCUS PHARMACEUTICALS BEGIN COLLABORATION TO DEVELOP NEW CANCER TREATMENTS

Locus Pharmaceuticals has entered into a cooperative research and development agreement (CRADA) with the U.S. National Cancer Institute (NCI) to develop novel anticancer therapies using Locus' proprietary, fragment-based, computational technology. The focus of the CRADA is Heat Shock Protein 90, a target of considerable current scientific interest because of its potential pathophysiological role in cancer and other cell proliferative diseases and disorders. Under the terms of the agreement, Locus will create one or more series of molecules in silico that will be designed to have high specific affinity for Hsp90.

Yahoo News (http://biz.yahoo.com/bw/050112/125127_1.html)